Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Alto Palo ALIM stock SEC Form 4 insiders trading
Alto has made over 1 trades of the Alimera Sciences stock since 2023, according to the Form 4 filled with the SEC. Most recently Alto sold 200,919 units of ALIM stock worth 313,434$ on 24 March 2023.
The largest trade Alto's ever made was selling 200,919 units of Alimera Sciences stock on 24 March 2023 worth over 313,434$. On average, Alto trades about 200,919 units every 0 days since 2023.
You can see the complete history of Alto Palo stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Alto Palo's mailing address?
Alto's mailing address filed with the SEC is 470, University Avenue, Palo Alto, Santa Clara County, California, 94301, United States.
Insiders trading at Alimera Sciences
Over the last 15 years, insiders at Alimera Sciences have traded over 14,704,529$ worth of Alimera Sciences stock and bought 8,598,915 units worth 59,337,384$ . The most active insiders traders include Capital, Llc Armistice Capi...、Nicole Vitullo、Jesse I Treu. On average, Alimera Sciences executives and independent directors trade stock every 32 days with the average trade being worth of 468,137$. The most recent stock trade was executed by Partners Lpjohnson David Ed... on 14 September 2023, trading 579,000 units of ALIM stock currently worth 1,962,810$.
What does Alimera Sciences do?
alimera, founded in june 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in aging populations. alimera's commitment to retina specialists and their patients is manifest in its product and in its development portfolio designed to treat early- and late-stage diseases. for more information, please visit www.alimerasciences.com. alimera's european operations are conducted from london by its subsidiary, alimera sciences limited.
What does Alimera Sciences's logo look like?
Complete history of Alto Palo stock trades at Alimera Sciences
Alimera Sciences executives and stock owners
Alimera Sciences executives and other stock owners filed with the SEC include:
-
Richard Eiswirth,
President, Chief Executive Officer, Director -
C. Daniel Myers,
Non-Executive Chairman of the Board -
Richard S. Eiswirth Jr.,
Pres, CEO & Director -
David Holland,
Chief Marketing Officer and Senior Vice President Corporate Communications and Managed Markets -
Philip Ashman,
Chief Operating Officer, Senior Vice President - Commercial Operations Europe -
David R. Holland,
Co-Founder, Chief Marketing Officer and Sr. VP of Corp. Communications & Managed Markets -
Dr. Philip Ashman,
COO & Sr. VP of Commercial Operations - Europe -
Charles Daniel Myers,
Non-Exec. Chairman & Consultant -
James Largent,
Lead Independent Director -
John Marco,
Investor Relations -
Mary Szela,
Independent Director -
John Snisarenko,
Independent Director -
Peter Pizzo,
Independent Director -
Garheng Kong,
Independent Director -
Brian Halak,
Independent Director -
Samer Kaba,
Chief Medical Officer -
Phil Jones,
Chief Financial Officer -
Dr. David Dyer,
Chief Retina Specialist -
Christopher S. Visick,
VP, Gen. Counsel & Sec. -
J. Philip Jones,
Chief Financial Officer -
Calvin W. Roberts,
Director -
Glen Bradley,
Director -
James E Deerfield Mgmt L.P....,
-
Mark J Brooks,
Director -
Kenneth Green,
SVP & Chief Scientific Officer -
L.P.Mitchell Kateo'driscoll...,
-
Alto Investors Lp Palo,
-
Russell Skibsted,
Chief Financial Officer & SVP -
Capital, Llc Armistice Capi...,
-
Patrick Lee,
10% owner -
Management Viii, L.L.C.Sofi...,
-
Partners Vi, L.P.Blair Jame...,
-
Vi Associates, L.P.Blair Ja...,
-
Jesse I Treu,
10% owner -
Venture Management Co Iv Ll...,
-
Philip R Tracy,
Director -
Susan Caballa,
SEE REMARKS -
Kathleen K Schoemaker,
10% owner -
Partners Vi, L.P. Domain,
10% owner -
James C Blair,
10% owner -
Nicole Vitullo,
10% owner -
Anders D Hove,
Director -
Bryce Youngren,
Director -
Brian H Dovey,
10% owner -
Vi Associates, L.P. Dp,
10% owner -
Associates Iv L P Venrock M...,
-
Associates Vi, Llc Mumma Mi...,
-
Associates Vii, Llc Mumma M...,
-
Associates V, Llc Mumma Mit...,
-
L.P.Bock Louis Cmitchell Ka...,
-
Adam Morgan,
Director -
Stanley Morgan,
10% owner -
Todd Michael Wood,
President of U.S. Operations -
Roger Sawhney,
Director -
Adam Velan Capital Investme...,
-
Partners Lpjohnson David Ed...,
-
Jason M. Werner,
Chief Operating Officer -
Erin Parsons,
-
Michael Kaseta,
-
Ross D De Mont,
-
Margaret Pax,
-
Elliot Maltz,
Chief Financial Officer